Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29;15(19):4807.
doi: 10.3390/cancers15194807.

Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes

Gennaro Musi  1   2 , Filippo Molinari  1 , Francesco A Mistretta  1   2 , Mattia Luca Piccinelli  1 , Sonia Guzzo  1 , Marco Tozzi  1 , Elena Lievore  1 , Oskar Blezien  1 , Matteo Fontana  1 , Antonio Cioffi  1 , Daniela Cullurà  3 , Elena Verri  3 , Maria Cossu Rocca  3 , Franco Nolè  3 , Matteo Ferro  1 , Ottavio de Cobelli  1   2 , Stefano Luzzago  1   2
Affiliations

Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes

Gennaro Musi et al. Cancers (Basel). .

Abstract

We tested the feasibility and oncological outcomes after penile-sparing surgery (PSS) for local recurrent penile cancer after a previous glansectomy/partial penectomy. We retrospectively analysed 13 patients (1997-2022) with local recurrence of penile cancer after a previous glansectomy or partial penectomy. All patients underwent PSS: circumcision, excision, or laser ablation. First, technical feasibility, treatment setting, and complications (Clavien-Dindo) were recorded. Second, Kaplan-Meier plots depicted overall and local recurrences over time. Overall, 11 (84.5%) vs. 2 (15.5%) patients were previously treated with glansectomy vs. partial penectomy. The median (IQR) time to disease recurrence was 56 (13-88) months. Six (46%) vs. two (15.5%) vs. five (38.5%) patients were treated with, respectively, local excision vs. local excision + circumcision vs. laser ablation. All procedures, except one, were performed in an outpatient setting. Only one Clavien-Dindo 2 complication was recorded. The median follow-up time was 41 months. Overall, three (23%) vs. four (30.5%) patients experienced local vs. overall recurrence, respectively. All local recurrences were safely treated with salvage surgery. In conclusion, we reported the results of a preliminary analysis testing safety, feasibility, and early oncological outcomes of PSS procedures for patients with local recurrence after previous glansectomy or partial penectomy. Stronger oncological outcomes should be tested in other series to optimise patient selection.

Keywords: excision; glansectomy; laser ablation; partial penectomy; penile cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Patient 1: Local recurrence at the level of the neoglans + foreskin at 56 months after glansectomy that underwent circumcision + excision. (B) Patient 3: Local recurrence at the level of the neoglans + foreskin at 9 months after glansectomy that underwent circumcision + excision.
Figure 2
Figure 2
Kaplan–Meier plots depicting recurrence-free survival rates in 13 patients with recurrent penile cancer treated with penile-sparing surgery after previous glansectomy or partial penectomy (1997–2022). (A) Local recurrence. (B) Overall recurrence (any local, regional, or systemic recurrence).
See this image and copyright information in PMC

References

    1. Hakenberg O.W., Compérat E.M., Minhas S., Necchi A., Protzel C., Watkin N. EAU guidelines on penile cancer: 2014 update. Eur. Urol. 2015;67:142–150. doi: 10.1016/j.eururo.2014.10.017. - DOI - PubMed
    1. Lindner A.K., Schachtner G., Steiner E., Kroiss A., Uprimny C., Steinkohl F., Horninger W., Heidegger I., Madersbacher S., Pichler R. Organ-sparing surgery of penile cancer: Higher rate of local recurrence yet no impact on overall survival. World J. Urol. 2020;38:417–424. doi: 10.1007/s00345-019-02793-9. - DOI - PMC - PubMed
    1. Djajadiningrat R.S., van Werkhoven E., Meinhardt W., van Rhijn B.W., Bex A., van der Poel H.G., Horenblas S. Penile sparing surgery for penile cancer—Does it affect survival? J. Urol. 2014;192:120–126. doi: 10.1016/j.juro.2013.12.038. - DOI - PubMed
    1. Baumgarten A., Chipollini J., Yan S., Ottenhof S.R., Tang D.H., Draeger D., Protzel C., Zhu Y., Ye D.-W., Hakenberg O.W., et al. Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. J. Urol. 2018;199:1233–1237. doi: 10.1016/j.juro.2017.10.045. - DOI - PubMed
    1. Luzzago S., Serino A., Aurilio G., Mistretta F.A., Piccinelli M.L., Lorusso V., Morelli M., Bianchi R., Catellani M., Cozzi G., et al. Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: Long-term oncological outcomes. Urol. Oncol. Semin. Orig. Investig. 2021;39:736.e1–736.e7. doi: 10.1016/j.urolonc.2021.06.020. - DOI - PubMed